Geographically, pharmerging markets are defined as those countries having a per capita GDP threshold of USD 25,000 and more than USD one billion spending growth from 2012 to 2016. Thus, the pharmerging markets includes 21 countries which are further categorized in Tier I, Tier II, Tier III countries based on the IMS defined parameters and the macroeconomic factors and respective pharmaceutical market forecasts. Tier I countries which includes China, dominated global pharmerging market because of higher Chinese government’s healthcare spending. However, Tier II countries which includes India, Brazil and Russia are project to grow significantly, owing to rapidly increasing aging population, rise in consumer awareness, favourable government policies, and modernization of healthcare infrastructure in this countries. The presence of numerous small and large vendors has made the pharmerging markets highly fragmented. Challenges such as price pressure, regulatory constraints, and competition from local and other international pharmaceutical companies are faced by most of the international pharmaceutical companies. Majority of pharmaceuticals giants are focusing on technological innovations, product extensions, and inorganic growth through mergers and acquisitions, which would intensify the market in near future.
This report identifies the global pharmerging market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global pharmerging market.
This report segments global pharmerging market on the basis of geography market as follows:
This report has been segmented into major geography market of pharmerging, such as: Tier I Countries (China), Tier II Countries (Brazil, India, and Russia), and Tier III Countries (Poland, Argentina, Turkey, Mexico, Venezuela, Romania, Saudi Arabia, Colombia, Vietnam, South Africa, Algeria, Thailand, Indonesia, Egypt, Pakistan, Nigeria, and Ukraine)
This report identifies all the major companies operating in the pharmerging market. Some of the major companies’ profiles in detail are as follows:
Merck & Co Inc.
Novartis International AG
Bristol-Myers Squibb Co
Boehringer Ingelheim Pharmaceuticals Corporation
Eli Lilly and Co.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis
4. Pharmerging Market– Market Forces
4.1.1. Rising in public and private healthcare insurance
4.1.2. Growing global pharmaceutical market
4.2.1. Higher cost of research and development
4.3.1. Emerging economies
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Pharmerging Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Pharmerging Market, By Geography
6.1. Tier I Countries (China)
6.2. Tier II Countries (Brazil, India, and Russia)
6.3. Tier III Countries (Poland, Argentina, Turkey, Mexico, Venezuela, Romania, Saudi Arabia, Colombia, Vietnam, South Africa, Algeria, Thailand, Indonesia, Egypt, Pakistan, Nigeria, and Ukraine)
7. Pharmerging – Market Entropy
7.2. Technological Developments
7.3. Merger & Acquisitions, and Joint Ventures
7.4. Supply- Contract
8. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
8.1. Merck & Co Inc.
8.2. Novartis International AG
8.3. Bristol-Myers Squibb Co
8.4. Boehringer Ingelheim Pharmaceuticals Corporation
8.5. Eli Lilly and Co.
8.6. Bayer HealthCare AG
8.7. AstraZeneca plc
8.8. Sanofi S.A.
8.9. Pfizer Inc.
8.10. Novo Nordisk A/S.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
9.3. Research Methodology
9.5. Compilation of Expert Insights